NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $5.64 +0.41 (+7.84%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precision BioSciences Stock (NASDAQ:DTIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$5.10▼$5.6450-Day Range$4.23▼$5.9152-Week Range$3.61▼$13.44Volume137,975 shsAverage Volume181,418 shsMarket Capitalization$59.50 millionP/E Ratio94.02Dividend YieldN/APrice Target$47.00Consensus RatingBuy Company OverviewPrecision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More… Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreDTIL MarketRank™: Precision BioSciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 95th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is 94.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is 94.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.42.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted21.96% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 13.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted21.96% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 13.35%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment1.81 News SentimentPrecision BioSciences has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Precision BioSciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have bought 181.64% more of their company's stock than they have sold. Specifically, they have bought $17,225.00 in company stock and sold $6,116.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Stock News HeadlinesPrecision BioSciences stock rises following FDA Fast Track designationApril 15, 2025 | in.investing.comPrecision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BApril 15, 2025 | businesswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 30, 2025 | Golden Portfolio (Ad)Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | businesswire.comAssessing Precision BioSciences: Insights From 4 Financial AnalystsMarch 21, 2025 | nasdaq.comPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025March 21, 2025 | businesswire.comPrecision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025March 20, 2025 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $3.81 on January 1st, 2025. Since then, DTIL shares have increased by 48.0% and is now trading at $5.64. View the best growth stocks for 2025 here. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) announced its quarterly earnings results on Wednesday, March, 26th. The company reported ($3.20) EPS for the quarter, missing the consensus estimate of ($2.09) by $1.11. The business earned $3.47 million during the quarter, compared to analyst estimates of $4.28 million. Precision BioSciences had a net margin of 11.48% and a negative trailing twelve-month return on equity of 23.69%. When did Precision BioSciences' stock split? Precision BioSciences's stock reverse split before market open on Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' top institutional investors include Moloney Securities Asset Management LLC (0.41%). Insiders that own company stock include Derek Jantz, J Jefferson Smith, John Alexander Kelly, Geno J Germano, Melinda Brown, Dario Scimeca and Alan List. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia Oyj (NOK) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings3/26/2025Today4/30/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$47.00 High Stock Price Target$60.00 Low Stock Price Target$34.00 Potential Upside/Downside+795.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.90 Trailing P/E Ratio87.51 Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,320,000.00 Net Margins11.48% Pretax Margin15.28% Return on Equity-23.69% Return on Assets-6.98% Debt Debt-to-Equity Ratio0.34 Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$68.70 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book1.16Miscellaneous Outstanding Shares10,550,000Free Float7,364,000Market Cap$55.39 million OptionableNo Data Beta1.59 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:DTIL) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.